Avinger Inc. (NASDAQ:AVGR) shares were down 2.5% during trading on Thursday . The company traded as low as $4.26 and last traded at $4.29, with a volume of 128,122 shares trading hands. The stock had previously closed at $4.40.

A number of analysts recently issued reports on the stock. Zacks Investment Research raised shares of Avinger from a “sell” rating to a “hold” rating in a research report on Tuesday, May 3rd. Canaccord Genuity reissued a “buy” rating on shares of Avinger in a research report on Tuesday, July 12th. Finally, BTIG Research reissued a “buy” rating and set a $18.00 target price on shares of Avinger in a research report on Friday, July 15th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $15.75.

The firm has a 50-day moving average price of $5.91 and a 200-day moving average price of $10.38. The company’s market capitalization is $53.68 million.

Avinger (NASDAQ:AVGR) last announced its quarterly earnings data on Monday, August 1st. The medical device company reported ($1.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.15) by $0.09. The firm had revenue of $4.70 million for the quarter, compared to analyst estimates of $3.05 million. On average, equities analysts forecast that Avinger Inc. will post ($4.16) earnings per share for the current year.

In other news, CEO Jeffrey M. Soinski acquired 57,100 shares of the firm’s stock in a transaction dated Tuesday, August 16th. The shares were bought at an average price of $3.50 per share, with a total value of $199,850.00. Following the acquisition, the chief executive officer now owns 59,345 shares of the company’s stock, valued at $207,707.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.